Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021;79:243–62.
Bokhorst LP, Valdagni R, Rannikko A, Kakehi Y, Pickles T, Bangma CH, et al. A decade of active surveillance in the PRIAS study: an update and evaluation of the criteria used to recommend a switch to active treatment. Eur Urol. 2016;70:954–60.
Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med. 2016;375:1415–24.
Stabile A, Orczyk C, Hosking-Jervis F, Giganti F, Arya M, Hindley RG, et al. Medium-term oncological outcomes in a large cohort of men treated with either focal or hemi-ablation using high-intensity focused ultrasonography for primary localized prostate cancer. BJU Int. 2019;124:431–40.
van Son MJ, Peters M, Reddy D, Shah TT, Hosking-Jervis F, Robinson S, et al. Conventional radical versus focal treatment for localised prostate cancer: a propensity score weighted comparison of 6-year tumour control. Prostate Cancer Prostatic Dis. 2021;24:1120–8.
Shah TT, Reddy D, Peters M, Ball D, Kim NH, Gomez EG, et al. Focal therapy compared to radical prostatectomy for non-metastatic prostate cancer: a propensity score-matched study. Prostate Cancer Prostatic Dis. 2021;24:567–74.
Rakauskas A, Marra G, Heidegger I, Kasivisvanathan V, Kretschmer A, Zattoni F, et al. Focal therapy for prostate cancer: complications and their treatment. Front Surg. 2021;8:696242.
Barry Delongchamps N, Schull A, Anract J, Abecassis JP, Zerbib M, Sibony M, et al. Feasibility and safety of targeted focal microwave ablation of the index tumor in patients with low to intermediate risk prostate cancer: results of the FOSTINE trial. PLoS One. 2021;16:e0252040.
Chiu PK, Teoh JY, Lau SY, Yee CH, Lo KL, Li KM, et al. Transperineal microwave ablation of prostate cancer guided by MRI ultrasound fusion and organ based tracking technology. Eur Urol Open Sci 2020;19(Suppl 2):e2344.
Fainberg JS, Al Awamlh BAH, DeRosa AP, Chesnut GT, Coleman JA, Lee T, et al. A systematic review of outcomes after thermal and nonthermal partial prostate ablation. Prostate Int. 2021;9:169–75.
Guillaumier S, Peters M, Arya M, Afzal N, Charman S, Dudderidge T, et al. A multicentre study of 5-year outcomes following focal therapy in treating clinically significant nonmetastatic prostate cancer. Eur Urol. 2018;74:422–9.
Durand M, Barret E, Galiano M, Rozet F, Sanchez-Salas R, Ahallal Y, et al. Focal cryoablation: a treatment option for unilateral low-risk prostate cancer. BJU Int. 2014;113:56–64.
van den Bos W, Scheltema MJ, Siriwardana AR, Kalsbeek AMF, Thompson JE, Ting F, et al. Focal irreversible electroporation as primary treatment for localized prostate cancer. BJU Int. 2018;121:716–24.
Taneja SS, Bennett J, Coleman J, Grubb R, Andriole G, Reiter RE, et al. Final results of a phase I/II multicenter trial of WST11 vascular targeted photodynamic therapy for hemi-ablation of the prostate in men with unilateral low risk prostate cancer performed in the United States. J Urol. 2016;196:1096–104.
Ukimura O, Desai MM, Palmer S, Valencerina S, Gross M, Abreu AL, et al. 3-Dimensional elastic registration system of prostate biopsy location by real-time 3-dimensional transrectal ultrasound guidance with magnetic resonance/transrectal ultrasound image fusion. J Urol. 2012;187:1080–6.